.

Department of Pathology, Microbiology, and Immunology

 

 

Maria Pia DePasquale, Ph.D.

 

 

Research Assistant Professor

Dept of Medicine

Dept of Pathology, Microbiology and Immunology

 

 

Contact Information

 

 

Office Location:
MCN A-2210

Phone: 615-322-6745

E-mail:  maria.pia.de.pasquale@vanderbilt.edu

 

Campus Mail address:

Dept of Medicine/Infectious Disease

MCN A-2200 (2582)

 

US Mailing address:
Vanderbilt University School of Medicine

Department of Medicine

Infectious Disease

MCN A-2200

Nashville, TN 37232-2582

 

 

 

Education

 

 

Ph.D, Univ of Milan, Italy
Postdoctoral Fellowship, MGH, Harvard Medical School, Boston Ma, USA Infectious Diseases
Ph.D., Univ of Milan, Italy
Doctor, Univ of Milan, Italy

 

 

Research Keywords

 

 


 

 

Research Description

 

 


 

 

Publications

 

 

De Pasquale, MP, Leigh Brown, AJ, Uvin, SC, Allega-Ingersoll, J, Caliendo, AM, Sutton, L, Donahue, S, D'Aquila, RT. Differences in HIV-1 pol sequences from female genital tract and blood during antiretroviral therapy. J Acquir Immune Defic Syndr, 34(1), 37-44, 2003

Olson, DP, Scadden, DT, D'Aquila, RT, De Pasquale, MP. The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1). AIDS, 16(13), 1743-7, 2002

La Seta Catamancio, S, De Pasquale, MP, Citterio, P, Kurtagic, S, Galli, M, Rusconi, S. In vitro evolution of the human immunodeficiency virus type 1 gag-protease region and maintenance of reverse transcriptase resistance following prolonged drug exposure. J Clin Microbiol, 39(3), 1124-9, 2001

Martinez-Picado, J, DePasquale, MP, Kartsonis, N, Hanna, GJ, Wong, J, Finzi, D, Rosenberg, E, Gunthard, HF, Sutton, L, Savara, A, Petropoulos, CJ, Hellmann, N, Walker, BD, Richman, DD, Siliciano, R, D'Aquila, RT. Antiretroviral resistance during successful therapy of HIV type 1 infection. Proc Natl Acad Sci U S A, 97(20), 10948-53, 2000

Mayer, KH, Boswell, S, Goldstein, R, Lo, W, Xu, C, Tucker, L, DePasquale, MP, D'Aquila, R, Anderson, DJ. Persistence of human immunodeficiency virus in semen after adding indinavir to combination antiretroviral therapy. Clin Infect Dis, 28(6), 1252-9, 1999

Hay, CM, Ruhl, DJ, Basgoz, NO, Wilson, CC, Billingsley, JM, DePasquale, MP, D'Aquila, RT, Wolinsky, SM, Crawford, JM, Montefiori, DC, Walker, BD. Lack of viral escape and defective in vivo activation of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes in rapidly progressive infection. J Virol, 73(7), 5509-19, 1999

Martinez-Picado, J, Sutton, L, De Pasquale, MP, Savara, AV, D'Aquila, RT. Human immunodeficiency virus type 1 cloning vectors for antiretroviral resistance testing. J Clin Microbiol, 37(9), 2943-51, 1999

Rusconi, S, De Pasquale, MP, Milazzo, L, Kurtagic, S, Bulgheroni, E, Citterio, P, Galazzi, M, La Seta Catamancio, S, Galli, M. Loss of lamivudine resistance in a zidovudine and lamivudine dual-resistant HIV-1 isolate after discontinuation of in vitro lamivudine drug pressure. Antivir Ther, 3(4), 203-7, 1998

Balotta, C, Bagnarelli, P, Riva, C, Valenza, A, Antinori, S, Colombo, MC, Sampaolesi, R, Violin, M, de Pasquale, MP, Moroni, M, Clementi, M, Galli, M. Comparable biological and molecular determinants in HIV type 1-infected long-term nonprogressors and recently infected individuals. AIDS Res Hum Retroviruses, 13(4), 337-41, 1997

Rusconi, S, De Pasquale, MP, Milazzo, L, Bulgheroni, E, Citterio, P, Kurtagic, S, d'Arminio-Monforte, A, Galli, M. In vitro effects of continuous pressure with zidovudine (ZDV) and lamivudine on a ZDV-resistant HIV-1 isolate. AIDS, 11(11), 1406-10, 1997

Rusconi, S, De Pasquale, MP, Milazzo, L, Moscatelli, G, Bulgheroni, E, Citterio, P, d'Arminio-Monforte, A, Moroni, M, Galli, M. Loss of antiviral effect owing to zidovudine and lamivudine double resistance in HIV-1-infected patients in an ongoing open-label trial. Antivir Ther, 2(1), 39-46, 1997

Rusconi S., Riva A., Cocchi F., Massironi E., Tornaghi R., De Maddalena C.,De Pasquale M.P., Galli M. In Vitro antibody production (IVAP) in the follow up of pediatric human immunodeficiency virus type 1-infected patients. Pediatric AIDS and HIV infection: fetus to adolescent , 8(2), 127-129, 1997

In vitro effects of continuous pressure with zidovudine (ZDV) and lamivudine on a ZDV-resistant HIV-1 isolate. Rusconi S., De Pasquale M.P., Milazzo L., Bulgheroni E., Citterio P., Kurtagic S., d'Arminio-Monforte A., Galli M. AIDS, 11(11), 1406-1410, 1997

Rusconi S, De Pasquale M.P, Milazzo L, Moscatelli G, Bulgheroni E, Citterio P, d'Arminio-Monforte A, Moroni M, Galli M. Loss of antiviral effect due to zidovudine (ZDV) and lamivudine (3TC) double resistance in HIV-1 infected patients in an ongoing open label trial. Antiviral Therapy , 2(1), 39-46, 1997

Rusconi, S, Riva, A, Cocchi, F, Massironi, E, Tornaghi, R, de Maddalena, C, de Pasquale, MP, Galli, M. In vitro antibody production (IVAP) in the follow-up of pediatric human immunodeficiency virus type 1-infected patients. Pediatr AIDS HIV Infect, 8(2), 127-9, 1997

Rusconi, S, De Pasquale, MP, Mainini, F, Bulgheroni, E, Kurtagic, S, Gori, A, Violin, M, Zanchetta, N, Moroni, M, Balotta, C, Galli, M. Viral load, viral phenotype modification, zidovudine susceptibility and reverse transcriptase mutations during the first 6 months of zidovudine monotherapy in HIV-1-infected people. Antivir Ther, 1(4), 211-9, 1996

Balotta, C, Vigan??, A, Riva, C, Colombo, MC, Salvaggio, A, de Pasquale, MP, Crupi, L, Papagno, L, Galli, M, Moroni, M, Principi, N. HIV type 1 phenotype correlates with the stage of infection in vertically infected children. AIDS Res Hum Retroviruses, 12(13), 1247-53, 1996

Principi, N, Marchisio, P, De Pasquale, MP, Massironi, E, Tornaghi, R, Vago, T. HIV-1 reverse transcriptase codon 215 mutation and clinical outcome in children treated with zidovudine. AIDS Res Hum Retroviruses, 10(6), 721-6, 1994